These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 25273395

  • 1. Short-term preoperative octreotide treatment for TSH-secreting pituitary adenoma.
    Fukuhara N, Horiguchi K, Nishioka H, Suzuki H, Takeshita A, Takeuchi Y, Inoshita N, Yamada S.
    Endocr J; 2015; 62(1):21-7. PubMed ID: 25273395
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas.
    Caron P, Arlot S, Bauters C, Chanson P, Kuhn JM, Pugeat M, Marechaud R, Teutsch C, Vidal E, Sassano P.
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2849-53. PubMed ID: 11397898
    [Abstract] [Full Text] [Related]

  • 3. Preoperative long-acting octreotide treatment for invasive thyrotropin-secreting pituitary macroadenoma after previous radioiodine thyroid ablation.
    Gruszka A, Zielinski GM, Kunert-Radek J.
    J Clin Neurosci; 2014 Feb; 21(2):340-2. PubMed ID: 23958483
    [Abstract] [Full Text] [Related]

  • 4. Long-term preoperative management of thyrotropin-secreting pituitary adenoma with octreotide.
    Iglesias P, Díez JJ.
    J Endocrinol Invest; 1998 Dec; 21(11):775-8. PubMed ID: 9972679
    [Abstract] [Full Text] [Related]

  • 5. Effect of preoperative use of long-acting octreotide on growth hormone secreting pituitary adenoma and transsphenoidal surgery.
    Yin J, Su CB, Xu ZQ, Yang Y, Ma WB, Tao W, Yang Z, Xia XW.
    Chin Med Sci J; 2005 Mar; 20(1):23-6. PubMed ID: 15844307
    [Abstract] [Full Text] [Related]

  • 6. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
    Plöckinger U, Reichel M, Fett U, Saeger W, Quabbe HJ.
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1416-23. PubMed ID: 7962337
    [Abstract] [Full Text] [Related]

  • 7. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.
    Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE, James RA, McConnell M, Roberts GA, Scanlon MF, Stewart PM, Teasdale E, Turner HE, Wass JA, Wardlaw JM.
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4554-63. PubMed ID: 12364434
    [Abstract] [Full Text] [Related]

  • 8. Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases.
    Yamada S, Fukuhara N, Horiguchi K, Yamaguchi-Okada M, Nishioka H, Takeshita A, Takeuchi Y, Ito J, Inoshita N.
    J Neurosurg; 2014 Dec; 121(6):1462-73. PubMed ID: 25237847
    [Abstract] [Full Text] [Related]

  • 9. [Octreotide in the diagnosis and treatment of pituitary thyrotropin-secreting adenoma].
    Chen S, Li M, Lian XL, Zeng ZP, Dai WX, Li F, Yu W, Wang RZ.
    Zhonghua Nei Ke Za Zhi; 2006 Nov; 45(11):910-3. PubMed ID: 17313878
    [Abstract] [Full Text] [Related]

  • 10. Management of coexisting thyrotropin/growth-hormone-secreting pituitary adenoma and papillary thyroid carcinoma: a therapeutic challenge.
    Nguyen HD, Galitz MS, Mai VQ, Clyde PW, Glister BC, Shakir MK.
    Thyroid; 2010 Jan; 20(1):99-103. PubMed ID: 20067380
    [Abstract] [Full Text] [Related]

  • 11. Short-term preoperative octreotide treatment of GH-secreting pituitary adenoma: predictors of tumor shrinkage.
    Oshino S, Saitoh Y, Kasayama S, Arita N, Ohnishi T, Kohara H, Izumoto S, Yoshimine T.
    Endocr J; 2006 Feb; 53(1):125-32. PubMed ID: 16543682
    [Abstract] [Full Text] [Related]

  • 12. Pathological study of thyrotropin-secreting pituitary adenoma: plurihormonality and medical treatment.
    Teramoto A, Sanno N, Tahara S, Osamura YR.
    Acta Neuropathol; 2004 Aug; 108(2):147-53. PubMed ID: 15185102
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Thyrotropin secreting pituitary adenoma effectively treated with octreotide.
    Fukuda T, Yokoyama N, Tamai M, Imaizumi M, Kimura H, Tominaga T, Ashizawa K, Kiriyama T, Yoshimine H, Ohishi K, Eguchi K.
    Intern Med; 1998 Dec; 37(12):1027-30. PubMed ID: 9932634
    [Abstract] [Full Text] [Related]

  • 15. Reduction in size of a thyrotropin- and gonadotropin-secreting pituitary adenoma treated with octreotide acetate (somatostatin analog).
    Sy RA, Bernstein R, Chynn KY, Kourides IA.
    J Clin Endocrinol Metab; 1992 Mar; 74(3):690-4. PubMed ID: 1740506
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR.
    Jenkins PJ, Emery M, Howling SJ, Evanson J, Besser GM, Monson JP.
    Horm Res; 2004 Mar; 62(5):227-32. PubMed ID: 15477693
    [Abstract] [Full Text] [Related]

  • 18. Thyroid storm induced by TSH-secreting pituitary adenoma: a case report.
    Fujio S, Ashari, Habu M, Yamahata H, Moinuddin FM, Bohara M, Arimura H, Nishijima Y, Arita K.
    Endocr J; 2014 Mar; 61(11):1131-6. PubMed ID: 25132171
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.
    Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, Lancranjan I, Lombardi G.
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2779-86. PubMed ID: 11397887
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.